Doxapram hasten the recovery from following total intravenous anesthesia with dexmedetomidine, propofol and remifentanil

Doxapram hasten the recovery from following total intravenous anesthesia with dexmedetomidine, propofol and remifentanil: a double-blind prospective randomized clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003346

Enrollment

Unknown

Registered

2013-06-11

Start date

2013-06-24

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea syndromes

Interventions

doxapram group and normal saline group:doxapram 1mg/kg iv vs normal saline

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Obstructive sleep apnea; 2. patients scheduled for elective uvulopalatopharyngoplasty for OSA; 3. aged from 18 to 60 years; male patients; 4. physical status: ASA class I and II; 5. written, informed consent was obtained from patients.

Exclusion criteria

Exclusion criteria: 1. patients had seirous cardiovascular, pulmonary, liver, kidney; 2. patients had neurological or psychic diseases. 3. patients had allergy history or other contraindications of demedotomidine,propofol,remifentanil and doxapram.

Design outcomes

Primary

Measure	Time frame
time to eye opening on verbal comman;	—

Secondary

Measure	Time frame
heart rate;Respiratory rate;BIS;	—

Countries

China

Contacts

Public ContactHuan-Liang Wang

timw4788@163.com+86 18765315562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026